+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Cryptococcosis Treatment Market - Global Forecast to 2030- Product Image
Cryptococcosis Treatment Market - Global Forecast to 2030- Product Image
Sale

Cryptococcosis Treatment Market - Global Forecast to 2030

  • PDF Icon

    Report

  • 187 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5012985
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Cryptococcosis Treatment Market grew from USD 7.77 billion in 2024 to USD 8.24 billion in 2025. It is expected to continue growing at a CAGR of 5.96%, reaching USD 11.00 billion by 2030.

Overview of Cryptococcosis and the Imperative for Advanced Treatment Strategies

Cryptococcosis, an invasive fungal infection caused by Cryptococcus species, presents significant clinical challenges for both immunocompromised and immunocompetent populations. Manifesting primarily as meningoencephalitis or pulmonary disease, it demands timely diagnosis and a nuanced therapeutic approach to reduce morbidity and mortality. Over the past decade, advancements in antifungal agents, evolving surgical techniques for refractory cases, and refined diagnostic protocols have reshaped treatment pathways. As global health systems confront increasing incidence among HIV-positive individuals, transplant recipients, and emerging cohorts, understanding the latest therapeutic innovations and market dynamics is critical. This executive summary delivers a concise overview of current trends, strategic considerations, and actionable insights designed to equip decision-makers with the intelligence required for informed investment, research prioritization, and patient care optimization.

Transformative Shifts Reshaping the Cryptococcosis Treatment Paradigm

Recent years have witnessed transformative shifts that are redefining cryptococcosis management from multiple angles. First, the introduction of novel antifungal compounds and combinations has expanded the armamentarium beyond traditional azoles and polyenes, enabling tailored regimens for varied patient profiles. Concurrently, minimally invasive surgical interventions such as refined lumbar drainage techniques have improved outcomes in cases complicated by elevated intracranial pressure. Furthermore, guidelines have evolved to recommend earlier initiation of antifungal therapy alongside immune reconstitution strategies in HIV-positive cohorts, underscoring the importance of multidisciplinary collaboration.

Technological advancements in rapid molecular diagnostics are also accelerating pathogen identification, allowing clinicians to move from empirical to targeted therapeutic approaches more swiftly. This shift reduces broad-spectrum exposure and mitigates resistance risks. Additionally, increased focus on translational research has catalyzed the development of immunomodulatory agents, including fusion proteins and monoclonal antibodies, aimed at bolstering host defenses. As the treatment landscape becomes more sophisticated, stakeholders must stay attuned to these paradigm changes to remain competitive and deliver optimal patient outcomes.

Assessing the Cumulative Impact of United States Tariffs Effective in 2025

The imposition of updated United States tariffs in 2025 on active pharmaceutical ingredients and finished antifungal products has had a multifaceted impact throughout the supply chain. Importers have faced higher costs for key raw materials, prompting several manufacturers to reassess sourcing strategies and explore localized production initiatives. This realignment has introduced short-term supply constraints for certain echinocandins and polyenes, while simultaneously incentivizing investment in domestic manufacturing infrastructure.

On the pricing front, healthcare providers have reported upward pressure on treatment expenditures, driving payers to negotiate new contracting models and outcome-based agreements. Research and development budgets have also been influenced; with escalating import costs, some organizations have reallocated funding toward in-house synthesis platforms and partnerships with contract development organizations located outside tariff zones. Ultimately, the 2025 tariff adjustments have accelerated the industry’s shift toward supply chain resilience, fostering closer collaboration between regulators, manufacturers, and distributors to ensure uninterrupted patient access.

In-Depth Segmentation Insights Driving Therapeutic and Market Dynamics

Analyzing the market through a treatment type lens reveals two primary categories: drug therapy and surgical intervention. Drug therapy encompasses antifungal agents, combination therapy, and monotherapy, with the antifungal agents subset further divided into azoles, echinocandins, and polyenes. Surgical intervention includes craniotomy, lumbar drainage, and ventricular drainage, each playing a critical role in managing severe central nervous system involvement.

When segmenting by patient type, the landscape comprises immunocompetent patients-adults and children-immunocompromised patients such as HIV-positive individuals, those on immunosuppressive therapy, and transplant recipients, as well as pregnant women who present unique therapeutic considerations. The route of administration spans inhalation, intravenous delivery through continuous or intermittent infusion, intravitreal application, and oral dosing, with each route offering distinct pharmacokinetic and compliance profiles.

Further distinctions emerge based on disease severity, classified as mild, moderate, or severe, and on stage of infection-initial, chronic, and refractory. Therapeutic approaches range from empirical therapy, subdivided into broad-spectrum and narrow-spectrum regimens, to supportive therapy and highly targeted interventions. The end-user environment includes clinics, home healthcare settings, and hospitals, the latter differentiated into private and public institutions. Additional segmentation by drug class contrasts broad-spectrum versus narrow-spectrum antifungals. Dose frequency categories-multiple doses, single dose, and variable dosing-reflect efforts to optimize adherence and pharmacodynamic efficacy. Lastly, biologics are segmented into fusion proteins and monoclonal antibodies, marking an emerging frontier in host-directed antifungal treatment.

Key Regional Trends Influencing Cryptococcosis Treatment Adoption

Regional analysis underscores distinct demand drivers and access challenges. In the Americas, established healthcare infrastructures facilitate early diagnosis and integrate advanced combination therapies, yet cost-containment pressures spur interest in generics and biosimilars. Europe, Middle East & Africa benefit from collaborative regulatory frameworks that accelerate approval pathways for innovative agents, though resource limitations in certain markets highlight the need for tiered pricing and capacity-building programs. In the Asia-Pacific region, rising prevalence among diverse patient cohorts and expanding healthcare budgets are fueling investments in local manufacturing and distribution networks, with governments incentivizing research partnerships to address unmet needs and ensure equitable treatment access.

Strategic Company Profiles Highlighting Competitive Innovation and Expansion

Leading industry players are shaping the competitive environment through robust research pipelines, strategic alliances, and portfolio diversification. Abbott Laboratories leverages its strong infectious disease franchise to explore combination therapies, while Amplyx Pharmaceuticals, Inc. focuses on novel antifungal candidates targeting refractory cases. Astellas Pharma Inc has prioritized targeted formulations designed for high-risk immunocompromised populations, and Bausch Health Companies Inc. emphasizes expanding generic antifungal offerings to enhance accessibility.

Bristol-Myers Squibb Company and Johnson & Johnson Services Inc. are investing in immunomodulatory biologics, with collaboration agreements for monoclonal antibodies and fusion proteins. Glenmark Pharmaceuticals Limited and Lupin Ltd are capitalizing on broad-spectrum antifungal generics, aiming to capture emerging markets through competitive pricing strategies. MATINAS BIOPHARMA HOLDINGS, INC. is advancing lipid-based formulations to optimize drug delivery, while Novartis AG and Pfizer, Inc. continue to refine existing azole and echinocandin portfolios, integrating patient-centric dosage regimens. NuCare Pharmaceuticals, Inc., Sigmapharm Laboratories, LLC, Teva Pharmaceutical Industries Ltd, and VIAMET PHARMACEUTICALS, Inc. each contribute specialized formulations and dosing innovations, collectively driving enhanced therapeutic outcomes across global markets.

Actionable Recommendations to Navigate Evolving Market Opportunities

  • Prioritize investment in local manufacturing capabilities and supply chain diversification to mitigate the impact of tariff fluctuations and ensure consistent product availability.
  • Accelerate clinical development of biologic therapies, including monoclonal antibodies and fusion proteins, by establishing strategic partnerships and adaptive trial designs that address high-risk patient populations.
  • Expand diagnostic infrastructure by integrating rapid molecular platforms and point-of-care testing to reduce time-to-treatment and improve patient outcomes.
  • Develop outcome-based contracting models with payers that align reimbursement with clinical efficacy and real-world evidence, fostering sustainable access to premium therapies.
  • Tailor commercial strategies to regional dynamics, leveraging tiered pricing in resource-constrained settings and premium service differentiation in established markets.

Conclusion: Aligning Strategic Initiatives with Emerging Treatment Needs

As the cryptococcosis treatment landscape continues to evolve, stakeholders must align strategic initiatives with emerging scientific advances and regulatory shifts. Embracing a multi-segment perspective-from treatment type and patient profile to route of administration and therapeutic approach-enables more precise targeting of clinical development and commercial efforts. Collaboration across the value chain, including partnerships between pharmaceutical innovators, diagnostic providers, and healthcare systems, will be instrumental in overcoming access barriers and optimizing patient outcomes. By proactively addressing supply chain vulnerabilities, investing in next-generation biologics, and refining outcome-based pricing models, organizations can establish competitive differentiation and drive sustained growth.

Market Segmentation & Coverage

This research report categorizes the Cryptococcosis Treatment Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Drug Therapy
    • Antifungal Agents
      • Azoles
      • Echinocandins
      • Polyenes
    • Combination Therapy
    • Monotherapy
  • Surgical Intervention
    • Craniotomy
    • Lumbar Drainage
    • Ventricular Drainage
  • Immunocompetent Patients
    • Adults
    • Children
  • Immunocompromised Patients
    • HIV-Positive Patients
    • Patients on Immunosuppressive Therapy
    • Transplant Recipients
  • Pregnant Women
  • Inhalation
  • Intravenous
    • Continuous Infusion
    • Intermittent Infusion
  • Intravitreal
  • Oral
  • Mild
  • Moderate
  • Severe
  • Chronic Stage
  • Initial Stage
  • Refractory Stage
  • Empirical Therapy
    • Broad-Spectrum
    • Narrow-Spectrum
  • Supportive Therapy
  • Targeted Therapy
  • Clinics
  • Home Healthcare
  • Hospitals
    • Private Hospitals
    • Public Hospitals
  • Broad-Spectrum Antifungal
  • Narrow-Spectrum Antifungal
  • Multiple Doses
  • Single Dose
  • Variable Dosing
  • Fusion Proteins
  • Monoclonal Antibodies

This research report categorizes the Cryptococcosis Treatment Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Cryptococcosis Treatment Market to delves into recent significant developments and analyze trends in each of the following companies:

  • Abbott Laboratories
  • Amplyx Pharmaceuticals, Inc.
  • Astellas Pharma Inc
  • Bausch Health Companies Inc.
  • Bristol-Myers Squibb Company
  • Glenmark Pharmaceuticals Limited
  • Johnson & Johnson Services inc.
  • Lupin Ltd
  • MATINAS BIOPHARMA HOLDINGS, INC.
  • Novartis AG
  • NuCare Pharmaceuticals, Inc.
  • Pfizer, Inc
  • Sigmapharm Laboratories, LLC
  • Teva Pharmaceutical Industries Ltd
  • VIAMET PHARMACEUTICALS, Inc.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Cryptococcosis Treatment Market, by Treatment Type
8.1. Introduction
8.2. Drug Therapy
8.2.1. Antifungal Agents
8.2.1.1. Azoles
8.2.1.2. Echinocandins
8.2.1.3. Polyenes
8.2.2. Combination Therapy
8.2.3. Monotherapy
8.3. Surgical Intervention
8.3.1. Craniotomy
8.3.2. Lumbar Drainage
8.3.3. Ventricular Drainage
9. Cryptococcosis Treatment Market, by Patient Type
9.1. Introduction
9.2. Immunocompetent Patients
9.2.1. Adults
9.2.2. Children
9.3. Immunocompromised Patients
9.3.1. HIV-Positive Patients
9.3.2. Patients on Immunosuppressive Therapy
9.3.3. Transplant Recipients
9.4. Pregnant Women
10. Cryptococcosis Treatment Market, by Route of Administration
10.1. Introduction
10.2. Inhalation
10.3. Intravenous
10.3.1. Continuous Infusion
10.3.2. Intermittent Infusion
10.4. Intravitreal
10.5. Oral
11. Cryptococcosis Treatment Market, by Disease Severity
11.1. Introduction
11.2. Mild
11.3. Moderate
11.4. Severe
12. Cryptococcosis Treatment Market, by Stage of Infections
12.1. Introduction
12.2. Chronic Stage
12.3. Initial Stage
12.4. Refractory Stage
13. Cryptococcosis Treatment Market, by Therapeutic Approach
13.1. Introduction
13.2. Empirical Therapy
13.2.1. Broad-Spectrum
13.2.2. Narrow-Spectrum
13.3. Supportive Therapy
13.4. Targeted Therapy
14. Cryptococcosis Treatment Market, by End-User
14.1. Introduction
14.2. Clinics
14.3. Home Healthcare
14.4. Hospitals
14.4.1. Private Hospitals
14.4.2. Public Hospitals
15. Cryptococcosis Treatment Market, by Drug Class
15.1. Introduction
15.2. Broad-Spectrum Antifungal
15.3. Narrow-Spectrum Antifungal
16. Cryptococcosis Treatment Market, by Dose Frequency
16.1. Introduction
16.2. Multiple Doses
16.3. Single Dose
16.4. Variable Dosing
17. Cryptococcosis Treatment Market, by Biologics
17.1. Introduction
17.2. Fusion Proteins
17.3. Monoclonal Antibodies
18. Americas Cryptococcosis Treatment Market
18.1. Introduction
18.2. Argentina
18.3. Brazil
18.4. Canada
18.5. Mexico
18.6. United States
19. Asia-Pacific Cryptococcosis Treatment Market
19.1. Introduction
19.2. Australia
19.3. China
19.4. India
19.5. Indonesia
19.6. Japan
19.7. Malaysia
19.8. Philippines
19.9. Singapore
19.10. South Korea
19.11. Taiwan
19.12. Thailand
19.13. Vietnam
20. Europe, Middle East & Africa Cryptococcosis Treatment Market
20.1. Introduction
20.2. Denmark
20.3. Egypt
20.4. Finland
20.5. France
20.6. Germany
20.7. Israel
20.8. Italy
20.9. Netherlands
20.10. Nigeria
20.11. Norway
20.12. Poland
20.13. Qatar
20.14. Russia
20.15. Saudi Arabia
20.16. South Africa
20.17. Spain
20.18. Sweden
20.19. Switzerland
20.20. Turkey
20.21. United Arab Emirates
20.22. United Kingdom
21. Competitive Landscape
21.1. Market Share Analysis, 2024
21.2. FPNV Positioning Matrix, 2024
21.3. Competitive Analysis
21.3.1. Abbott Laboratories
21.3.2. Amplyx Pharmaceuticals, Inc.
21.3.3. Astellas Pharma Inc
21.3.4. Bausch Health Companies Inc.
21.3.5. Bristol-Myers Squibb Company
21.3.6. Glenmark Pharmaceuticals Limited
21.3.7. Johnson & Johnson Services inc.
21.3.8. Lupin Ltd
21.3.9. MATINAS BIOPHARMA HOLDINGS, INC.
21.3.10. Novartis AG
21.3.11. NuCare Pharmaceuticals, Inc.
21.3.12. Pfizer, Inc
21.3.13. Sigmapharm Laboratories, LLC
21.3.14. Teva Pharmaceutical Industries Ltd
21.3.15. VIAMET PHARMACEUTICALS, Inc.
22. ResearchAI
23. ResearchStatistics
24. ResearchContacts
25. ResearchArticles
26. Appendix
List of Figures
FIGURE 1. CRYPTOCOCCOSIS TREATMENT MARKET MULTI-CURRENCY
FIGURE 2. CRYPTOCOCCOSIS TREATMENT MARKET MULTI-LANGUAGE
FIGURE 3. CRYPTOCOCCOSIS TREATMENT MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2024 VS 2030 (%)
FIGURE 14. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY STAGE OF INFECTIONS, 2024 VS 2030 (%)
FIGURE 16. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY STAGE OF INFECTIONS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY THERAPEUTIC APPROACH, 2024 VS 2030 (%)
FIGURE 18. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY THERAPEUTIC APPROACH, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 20. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 22. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DOSE FREQUENCY, 2024 VS 2030 (%)
FIGURE 24. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DOSE FREQUENCY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2024 VS 2030 (%)
FIGURE 26. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. UNITED STATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 30. UNITED STATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 31. ASIA-PACIFIC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 32. ASIA-PACIFIC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 33. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 34. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 35. CRYPTOCOCCOSIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 36. CRYPTOCOCCOSIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. CRYPTOCOCCOSIS TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ANTIFUNGAL AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ECHINOCANDINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ANTIFUNGAL AGENTS, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CRANIOTOMY, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY LUMBAR DRAINAGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY VENTRICULAR DRAINAGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY IMMUNOCOMPETENT PATIENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CHILDREN, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY IMMUNOCOMPETENT PATIENTS, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY IMMUNOCOMPROMISED PATIENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HIV-POSITIVE PATIENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENTS ON IMMUNOSUPPRESSIVE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY TRANSPLANT RECIPIENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY IMMUNOCOMPROMISED PATIENTS, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PREGNANT WOMEN, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INHALATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CONTINUOUS INFUSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTERMITTENT INFUSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVITREAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY MILD, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY MODERATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY SEVERE, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY STAGE OF INFECTIONS, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CHRONIC STAGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INITIAL STAGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY REFRACTORY STAGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY EMPIRICAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY BROAD-SPECTRUM, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NARROW-SPECTRUM, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY EMPIRICAL THERAPY, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY BROAD-SPECTRUM ANTIFUNGAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NARROW-SPECTRUM ANTIFUNGAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DOSE FREQUENCY, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY MULTIPLE DOSES, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY SINGLE DOSE, BY REGION, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY VARIABLE DOSING, BY REGION, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 70. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY FUSION PROTEINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 71. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ANTIFUNGAL AGENTS, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY IMMUNOCOMPETENT PATIENTS, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY IMMUNOCOMPROMISED PATIENTS, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY STAGE OF INFECTIONS, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 84. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY EMPIRICAL THERAPY, 2018-2030 (USD MILLION)
TABLE 85. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 86. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 87. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 88. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DOSE FREQUENCY, 2018-2030 (USD MILLION)
TABLE 89. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 90. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 91. ARGENTINA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 92. ARGENTINA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 93. ARGENTINA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ANTIFUNGAL AGENTS, 2018-2030 (USD MILLION)
TABLE 94. ARGENTINA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
TABLE 95. ARGENTINA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 96. ARGENTINA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY IMMUNOCOMPETENT PATIENTS, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY IMMUNOCOMPROMISED PATIENTS, 2018-2030 (USD MILLION)
TABLE 98. ARGENTINA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY STAGE OF INFECTIONS, 2018-2030 (USD MILLION)
TABLE 102. ARGENTINA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 103. ARGENTINA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY EMPIRICAL THERAPY, 2018-2030 (USD MILLION)
TABLE 104. ARGENTINA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 105. ARGENTINA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 106. ARGENTINA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 107. ARGENTINA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DOSE FREQUENCY, 2018-2030 (USD MILLION)
TABLE 108. ARGENTINA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 109. BRAZIL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 110. BRAZIL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 111. BRAZIL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ANTIFUNGAL AGENTS, 2018-2030 (USD MILLION)
TABLE 112. BRAZIL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
TABLE 113. BRAZIL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 114. BRAZIL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY IMMUNOCOMPETENT PATIENTS, 2018-2030 (USD MILLION)
TABLE 115. BRAZIL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY IMMUNOCOMPROMISED PATIENTS, 2018-2030 (USD MILLION)
TABLE 116. BRAZIL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 117. BRAZIL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 118. BRAZIL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 119. BRAZIL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY STAGE OF INFECTIONS, 2018-2030 (USD MILLION)
TABLE 120. BRAZIL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 121. BRAZIL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY EMPIRICAL THERAPY, 2018-2030 (USD MILLION)
TABLE 122. BRAZIL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 123. BRAZIL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 124. BRAZIL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 125. BRAZIL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DOSE FREQUENCY, 2018-2030 (USD MILLION)
TABLE 126. BRAZIL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 127. CANADA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 128. CANADA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 129. CANADA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ANTIFUNGAL AGENTS, 2018-2030 (USD MILLION)
TABLE 130. CANADA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
TABLE 131. CANADA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 132. CANADA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY IMMUNOCOMPETENT PATIENTS, 2018-2030 (USD MILLION)
TABLE 133. CANADA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY IMMUNOCOMPROMISED PATIENTS, 2018-2030 (USD MILLION)
TABLE 134. CANADA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 135. CANADA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 136. CANADA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 137. CANADA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY STAGE OF INFECTIONS, 2018-2030 (USD MILLION)
TABLE 138. CANADA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 139. CANADA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY EMPIRICAL THERAPY, 2018-2030 (USD MILLION)
TABLE 140. CANADA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 141. CANADA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 142. CANADA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 143. CANADA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DOSE FREQUENCY, 2018-2030 (USD MILLION)
TABLE 144. CANADA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 145. MEXICO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 146. MEXICO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 147. MEXICO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ANTIFUNGAL AGENTS, 2018-2030 (USD MILLION)
TABLE 148. MEXICO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
TABLE 149. MEXICO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 150. MEXICO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY IMMUNOCOMPETENT PATIENTS, 2018-2030 (USD MILLION)
TABLE 151. MEXICO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY IMMUNOCOMPROMISED PATIENTS, 2018-2030 (USD MILLION)
TABLE 152. MEXICO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 153. MEXICO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 154. MEXICO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 155. MEXICO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY STAGE OF INFECTIONS, 2018-2030 (USD MILLION)
TABLE 156. MEXICO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 157. MEXICO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY EMPIRICAL THERAPY, 2018-2030 (USD MILLION)
TABLE 158. MEXICO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 159. MEXICO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 160. MEXICO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 161. MEXICO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DOSE FREQUENCY, 2018-2030 (USD MILLION)
TABLE 162. MEXICO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 163. UNITED STATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 164. UNITED STATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 165. UNITED STATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ANTIFUNGAL AGENTS, 2018-2030 (USD MILLION)
TABLE 166. UNITED STATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
TABLE 167. UNITED STATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 168. UNITED STATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY IMMUNOCOMPETENT PATIENTS, 2018-2030 (USD MILLION)
TABLE 169. UNITED STATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY IMMUNOCOMPROMISED PATIENTS, 2018-2030 (USD MILLION)
TABLE 170. UNITED STATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 171. UNITED STATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 172. UNITED STATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 173. UNITED STATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY STAGE OF INFECTIONS, 2018-2030 (USD MILLION)
TABLE 174. UNITED STATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 175. UNITED STATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY EMPIRICAL THERAPY, 2018-2030 (USD MILLION)
TABLE 176. UNITED STATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 177. UNITED STATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 178. UNITED STATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 179. UNITED STATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DOSE FREQUENCY, 2018-2030 (USD MILLION)
TABLE 180. UNITED STATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 181. UNITED STATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 182. ASIA-PACIFIC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 183. ASIA-PACIFIC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 184. ASIA-PACIFIC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ANTIFUNGAL AGENTS, 2018-2030 (USD MILLION)
TABLE 185. ASIA-PACIFIC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
TABLE 186. ASIA-PACIFIC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 187. ASIA-PACIFIC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY IMMUNOCOMPETENT PATIENTS, 2018-2030 (USD MILLION)
TABLE 188. ASIA-PACIFIC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY IMMUNOCOMPROMISED PATIENTS, 2018-2030 (USD MILLION)
TABLE 189. ASIA-PACIFIC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 190. ASIA-PACIFIC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 191. ASIA-PACIFIC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 192. ASIA-PACIFIC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY STAGE OF INFECTIONS, 2018-2030 (USD MILLION)
TABLE 193. ASIA-PACIFIC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 194. ASIA-PACIFIC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY EMPIRICAL THERAPY, 2018-2030 (USD MILLION)
TABLE 195. ASIA-PACIFIC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 196. ASIA-PACIFIC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 197. ASIA-PACIFIC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 198. ASIA-PACIFIC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DOSE FREQUENCY, 2018-2030 (USD MILLION)
TABLE 199. ASIA-PACIFIC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 200. ASIA-PACIFIC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 201. AUSTRALIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 202. AUSTRALIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 203. AUSTRALIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ANTIFUNGAL AGENTS, 2018-2030 (USD MILLION)
TABLE 204. AUSTRALIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
TABLE 205. AUSTRALIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 206. AUSTRALIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY IMMUNOCOMPETENT PATIENTS, 2018-2030 (USD MILLION)
TABLE 207. AUSTRALIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY IMMUNOCOMPROMISED PATIENTS, 2018-2030 (USD MILLION)
TABLE 208. AUSTRALIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 209. AUSTRALIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 210. AUSTRALIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 211. AUSTRALIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY STAGE OF INFECTIONS, 2018-2030 (USD MILLION)
TABLE 212. AUSTRALIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 213. AUSTRALIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY EMPIRICAL THERAPY, 2018-2030 (USD MILLION)
TABLE 214. AUSTRALIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 215. AUSTRALIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 216. AUSTRALIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 217. AUSTRALIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DOSE FREQUENCY, 2018-2030 (USD MILLION)
TABLE 218. AUSTRALIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 219. CHINA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 220. CHINA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 221. CHINA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ANTIFUNGAL AGENTS, 2018-2030 (USD MILLION)
TABLE 222. CHINA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
TABLE 223. CHINA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 224. CHINA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY IMMUNOCOMPETENT PATIENTS, 2018-2030 (USD MILLION)
TABLE 225. CHINA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY IMMUNOCOMPROMISED PATIENTS, 2018-2030 (USD MILLION)
TABLE 226. CHINA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 227. CHINA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 228. CHINA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 229. CHINA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY STAGE OF INFECTIONS, 2018-2030 (USD MILLION)
TABLE 230. CHINA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 231. CHINA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY EMPIRICAL THERAPY, 2018-2030 (USD MILLION)
TABLE 232. CHINA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 233. CHINA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 234. CHINA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 235. CHINA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DOSE FREQUENCY, 2018-2030 (USD MILLION)
TABLE 236. CHINA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 237. INDIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 238. INDIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 239. INDIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ANTIFUNGAL AGENTS, 2018-2030 (USD MILLION)
TABLE 240. INDIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
TABLE 241. INDIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 242. INDIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY IMMUNOCOMPETENT PATIENTS, 2018-2030 (USD MILLION)
TABLE 243. INDIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY IMMUNOCOMPROMISED PATIENTS, 2018-2030 (USD MILLION)
TABLE 244. INDIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 245. INDIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 246. INDIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 247. INDIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY STAGE OF INFECTIONS, 2018-2030 (USD MILLION)
TABLE 248. INDIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 249. INDIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY EMPIRICAL THERAPY, 2018-2030 (USD MILLION)
TABLE 250. INDIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 251. INDIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 252. INDIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 253. INDIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DOSE FREQUENCY, 2018-2030 (USD MILLION)
TABLE 254. INDIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 255. INDONESIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 256. INDONESIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 257. INDONESIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ANTIFUNGAL AGENTS, 2018-2030 (USD MILLION)
TABLE 258. INDONESIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
TABLE 259. INDONESIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 260. INDONESIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY IMMUNOCOMPETENT PATIENTS, 2018-2030 (USD MILLION)
TABLE 261. INDONESIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY IMMUNOCOMPROMISED PATIENTS, 2018-2030 (USD MILLION)
TABLE 262. INDONESIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 263. INDONESIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 264. INDONESIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 265. INDONESIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY STAGE OF INFECTIONS, 2018-2030 (USD MILLION)
TABLE 266. INDONESIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 267. INDONESIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY EMPIRICAL THERAPY, 2018-2030 (USD MILLION)
TABLE 268. INDONESIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 269. INDONESIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 270. INDONESIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 271. INDONESIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DOSE FREQUENCY, 2018-2030 (USD MILLION)
TABLE 272. INDONESIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 273. JAPAN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 274. JAPAN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 275. JAPAN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ANTIFUNGAL AGENTS, 2018-2030 (USD MILLION)
TABLE 276. JAPAN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
TABLE 277. JAPAN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 278. JAPAN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY IMMUNOCOMPETENT PATIENTS, 2018-2030 (USD MILLION)
TABLE 279. JAPAN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY IMMUNOCOMPROMISED PATIENTS, 2018-2030 (USD MILLION)
TABLE 280. JAPAN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 281. JAPAN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 282. JAPAN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 283. JAPAN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY STAGE OF INFECTIONS, 2018-2030 (USD MILLION)
TABLE 284. JAPAN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 285. JAPAN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY EMPIRICAL THERAPY, 2018-2030 (USD MILLION)
TABLE 286. JAPAN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 287. JAPAN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 288. JAPAN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 289. JAPAN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DOSE FREQUENCY, 2018-2030 (USD MILLION)
TABLE 290. JAPAN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 291. MALAYSIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 292. MALAYSIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 293. MALAYSIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ANTIFUNGAL AGENTS, 2018-2030 (USD MILLION)
TABLE 294. MALAYSIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
TABLE 295. MALAYSIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 296. MALAYSIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY IMMUNOCOMPETENT PATIENTS, 2018-2030 (USD MILLION)
TABLE 297. MALAYSIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY IMMUNOCOMPROMISED PATIENTS, 2018-2030 (USD MILLION)
TABLE 298. MALAYSIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 299. MALAYSIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 300. MALAYSIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 301. MALAYSIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY STAGE OF INFECTIONS, 2018-2030 (USD MILLION)
TABLE 302. MALAYSIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 303. MALAYSIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY EMPIRICAL THERAPY, 2018-2030 (USD MILLION)
TABLE 304. MALAYSIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 305. MALAYSIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 306. MALAYSIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 307. MALAYSIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DOSE FREQUENCY, 2018-2030 (USD MILLION)
TABLE 308. MALAYSIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 309. PHILIPPINES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 310. PHILIPPINES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 311. PHILIPPINES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ANTIFUNGAL AGENTS, 2018-2030 (USD MILLION)
TABLE 312. PHILIPPINES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
TABLE 313. PHILIPPINES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 314. PHILIPPINES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY IMMUNOCOMPETENT PATIENTS, 2018-2030 (USD MILLION)
TABLE 315. PHILIPPINES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY IMMUNOCOMPROMISED PATIENTS, 2018-2030 (USD MILLION)
TABLE 316. PHILIPPINES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 317. PHILIPPINES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 318. PHILIPPINES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 319. PHI

Companies Mentioned

  • Abbott Laboratories
  • Amplyx Pharmaceuticals, Inc.
  • Astellas Pharma Inc
  • Bausch Health Companies Inc.
  • Bristol-Myers Squibb Company
  • Glenmark Pharmaceuticals Limited
  • Johnson & Johnson Services inc.
  • Lupin Ltd
  • MATINAS BIOPHARMA HOLDINGS, INC.
  • Novartis AG
  • NuCare Pharmaceuticals, Inc.
  • Pfizer, Inc
  • Sigmapharm Laboratories, LLC
  • Teva Pharmaceutical Industries Ltd
  • VIAMET PHARMACEUTICALS, Inc.

Methodology

Loading
LOADING...

Related Topics

Related Reports

Cryptococcosis Treatment - Global Strategic Business Report - Product Image

Cryptococcosis Treatment - Global Strategic Business Report

  • Report
  • 193 Pages
  • Global
From
Cryptococcosis Therapeutics - Global Strategic Business Report - Product Image

Cryptococcosis Therapeutics - Global Strategic Business Report

  • Report
  • 473 Pages
  • Global
From
Cryptococcosis - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Cryptococcosis - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Cryptococcosis - Pipeline Insight, 2025 - Product Image

Cryptococcosis - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.